Spectrum Pharmaceuticals (SPPI) announced the U.S. FDA has granted approval of EVOMELA for use in two indications: use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma; and for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
Spectrum Pharmaceuticals gained global development and commercialization rights to EVOMELA from Ligand Pharma (LGND) in March 2013. Ligand received a license fee and is eligible to receive milestone payments, as well as royalties following potential commercialization.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.